# Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan

> **NCT01424319** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 58 (actual)

## Conditions studied

- Chronic Kidney Disease
- Diabetic Nephropathy

## Interventions

- **DRUG:** Atrasentan low dose group
- **DRUG:** Atrasentan high dose group
- **DRUG:** Atrasentan placebo group

## Key facts

- **NCT ID:** NCT01424319
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2017-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01424319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01424319, "Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01424319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*